Action spectrum for the photolysis of Myxococcus xanthus.
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Myxothiazol is shown to be 4-(6-carbamoyl-3,5-dimethoxy-4-methylhexa-1E,5E-dienyl)-2'-(1,6-dimethylhepta-2 E,4E-dienyl)-2,4'-bithiazole by spectroscopic (mainly 1H NMR, 15C NMR and mass spectroscopic) and chemical methods.
Explore the source record for details and available documents.
Myxovalargin A has two modes of action. At low concentrations (below 1 microgram/ml) it inhibits bacterial protein synthesis specifically and instantaneously. In vitro experiments suggest that it interferes with the binding of aminoacyl tRNA to the A site of the ribosome. At higher concentrations (above 5 micrograms/ml), or upon prolonged incubation, the antibiotic damages cell membranes. This leads to secondary effects, like decreased O2 consumption or instant break down of RNA synthesis, and may be the reason for the irreversibility of the antibiotic action. The membrane effect is not restricted to prokaryotes and may explain the high toxicity of the compound for higher organisms.
Explore the source record for details and available documents.
Myxobacteria and a variety of strains of Escherichia coli contain an unusual extrachromosomal element, a small single-stranded branched copolymer of DNA and RNA (msDNA). Interest in msDNA stems from the presence of a 2'-5' linkage between its DNA and RNA moieties and the possible involvement of reverse transcriptase in its synthesis. Two groups have proposed a model for the synthesis of msDNA that involves the following sequence of events: 1) synthesis of an RNA precursor; 2) addition of a dNTP in a 2'-5' linkage to the RNA precursor (branch priming); 3) synthesis by reverse transcriptase of complementary DNA on the primed RNA precursor; 4) concomitant processing of the RNA precursor by RNase H; and 5) further processing of the RNA precursor by RNase H; and 5) further processing of the branched polymer. The branch priming hypothesis (step 2) was originally based on pulse-chase experiments using a lengthy pulse of 30-min duration. Our experiments with shorter pulse durations demonstrate a variety of intermediate forms not predicted by this model. Specifically, we find that early in synthesis, intermediate msDNA forms appear that are apparently not branch-linked to corresponding RNA moieties. The concomitant RNase H hypothesis (step 4) was based in part on intermediate trapping experiments using dideoxy NTPs to interrupt msDNA synthesis. These experiments showed an apparent complementary relationship between DNA length and RNA length in the trapped forms. In contrast, our experiments show that DNA elongation and RNA processing follow different kinetics. These results suggest an alternate model for synthesis of msDNA in which a conventionally primed DNA moiety is joined with the RNA moiety in a branch ligation event taking place several minutes after the synthesis of both moieties.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.